AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400355-T1: [Translated] DISPERSANT

Basic and acid dispersants derived from branched alkyl aliphatic acids and alcohols and one or more hydroxy carboxylic acid or lactone to give a polyoxyalkylenecarbonyl chain (POAC) having a terminal carboxylic acid group (TPOAC acid) or terminal hydroxy group (TPOAC alcohol). Preferred basic dispersants are obtained by reaching one or more TPOAC acids with a polyamine or polyimine such as polyethyleneimine and preferred anionic dispersants are prepared by forming a phosphate ester of a TPOAC alcohol.
The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma

The anti-PM/Scl autoantibodies are known to characterize a subset of autoimmune patients with myositis, scleroderma (Scl), and the PM/Scl overlap syndrome. The major autoantigens that are recognized by anti-PM/Scl autoantibodies are designated PM/Scl-100 and PM/Scl-75. These autoantigens have been reported to associate into a large complex consisting of 11 to 16 proteins and to play a role in ribosome synthesis. Recently, it was discovered that the PM/Scl complex is the human counterpart of the yeast (Saccharomyces cerevisiae) exosome, which is an RNA-processing complex consisting of 11 3' → 5' exoribonucleases. To date, 10 human exosome components have been identified, although only some of these were studied in more detail. In this review, we discuss some recent advances in the characterization of the PM/Scl complex.
Review and Validation of the Analytic Syntax Used to Produce CFSR Statewide Data Indicators

This report presents findings from a systematic review and verification of the Observed Performance, Data Quality Check, and Risk-Standardized Performance (RSP) syntax used to produce Child and Family Services Reviews (CFSR) statewide data indicators for the Children’s Bureau (CB).

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401341-T1: [Translated] VACCINES CONTAINING OMP85 PROTEINS FROM NEISSERIA GONORRHOEAE AND NEISSERIA MENINGITIDIS

Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof, as well as homologs and fusion products thereof, are useful in vaccine compositions for use in the protection of subjects against Neisserial disease such as non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies developed to these proteins and peptides are also useful in the vaccine compositions.
2010 State Profile — Texas

This state profile includes data from facilities in Texas that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Texas. In Texas, 454 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 33,113 clients in substance abuse treatment on March 31, 2010. The survey response rate in Texas was 89.2%.
DEV DQS Obesity among children and adolescents aged 2–19 years, by selected characteristics: United States

Data on obesity among children and adolescents aged 2-19 years in the United States, by selected characteristics, including sex, age, race, Hispanic origin, and poverty level. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey.
Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.
Patent AT-E401373-T1: [Translated] GLASS FIBER REINFORCED THERMOPLASTIC COMPOSITE MATERIAL

A translucent composition comprises an aromatic polycarbonate (PC) and poly(1,4-cyclohexane dimethylene 1,4-cyclohexanedicarboxylate) (PCCD), with the weight ratio of PC to PCCD in the range of 30 to 85 PC to 70 to 15 PCCD and a glass fiber at least about 0.75 mm in length in an amount of from about 1 to about 50 wt.% of the composition wherein the refractive index of the PC/PCCD mixture and the glass fiber matched between the range of about 1.540 to about 1.570.
Deaths, Death Rates and Age-Sex Adjusted Death Rates for Selected Causes of Death by Resident County, New York State: Beginning 2018

This dataset contains the number of New York State deaths, death rates and age-sex adjusted death rates for selected causes of death by resident county. The data presented here may differ from the Vital Statistics tables on the Department public website due to data updates. For more information, visit  https://www.health.ny.gov/statistics/vital_statistics/vs_reports_tables_list.htm,  where information from this dataset is presented in tabular form in Tables 38-40.
Compound 525221: Dodecyl heptafluorobutanoate

Chemical compound data from PubChem database. IUPAC Name: dodecyl 2,2,3,3,4,4,4-heptafluorobutanoate. Molecular Formula: C16H25F7O2. Molecular Weight: 382.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399537-T1: [Translated] PHARMACEUTICAL COMPOSITIONS CONTAINING ATORVASTATIN, PRODUCED WITHOUT GRANULATION

Chemical patent from PubChem database. Patent Number: AT-E399537-T1. Title: Sustained Release Formulation. Filing Date: 2009-05-25. Inventors: Smith, John A., Johnson, Mary B.. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: A61K, A61L, A61F. This patent covers 25 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
The Proliferation REduction with Vascular ENergy Trial (PREVENT)

PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with 32P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy.
COVID-19 Equity Metrics (PAUSED)

__Note:__ This dataset is on hiatus.

CDPH strives to respond equitably to the COVID-19 pandemic and is therefore interested in how different communities are impacted. Collecting and reporting health equity data helps to identify health disparities and improve the state’s response. To that end, CDPH tracks cases, deaths, and testing by race and ethnicity as well as other social determinants of health, such as income, crowded housing, and access to health insurance.

During the response, CDPH used a health equity metric, defined as the positivity rate in the most disproportionately-impacted communities according to the Healthy Places Index. The purpose of this metric was to ensure California reopened its economy safely by reducing disease transmission in all communities. This metric is tracked and reported in comparison to statewide positivity rate. More information is available at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/CaliforniaHealthEquityMetric.aspx.

Data completeness is also critical to addressing inequities. CDPH reports data completeness by race and ethnicity, sexual orientation, and gender identity to better understand missingness in the data.

Health equity data is updated weekly. Data may be suppressed based on county population or total counts.

For more information on California’s commitment to health equity, please see https://covid19.ca.gov/equity/
Research Article: Journal of Biomedicine and Biotechnology

An intense suppression of T cell proliferation to mitogens and to
antigens is observed in a large number of parasitic infections.
The impairment of T cell proliferation also occurred during the
acute phase of Chagas' disease, caused by the intracellular
protozoan parasite Trypanosoma cruzi. A wealth of
evidence has accumulated that illustrates the ability of
T. cruzi released molecules to influence directly a
variety of diverse immunological functions. In this paper, we
review the data concerning the immunoregulatory effects of
T. cruzi Tc24 (a B cell activator antigen) and Tc52 (an
immunosuppressive protein) released molecules on the host immune
system. The gene targeting approach developed to further explore
the biological function(s) of Tc52 molecule, revealed interesting
unexpected functional properties. Indeed, in addition to its
immunusuppressive activity a direct or indirect involvement of
Tc52 gene product alone or in combination with other
cellular components in T. cruzi differentiation control
mechanisms have been evidenced. Moreover, targeted Tc52
replacement allowed the obtention of parasite mutants exhibiting
low virulence in vitro and in vivo. Thus, the
generation of a complete deficiency state of virulence factors by
gene targeting should provide a means to assess the importance of
these factors in the pathophysiological processes and disease
progression. It is hoped that such approaches might allow
rational design of tools to control T. cruzi
infections.
Patent AT-E401740-T1: [Translated] SECURE RECORDING AND PLAYBACK OF MEDIA PROGRAMS USING MUTUALLY MATCHED RECEIVER AND STORAGE DEVICE

A method and apparatus for storing and retrieving program material for subsequent replay is disclosed. The method comprises the steps of receiving a data stream comprising the program material encrypted according to a first (CW) encryption key, decrypting the program material; re-encrypting the program material according to a second encryption key (516); and storing the re-encrypted material in a media storage device (528). The program material is played back by retrieving the re-encrypted material (518) from the media storage device (528) and decrypting the re-encrypted program material. In one embodiment, the second encryption key (516) is derived from metadata describing replay rights. In a further embodiment, the media storage device (528) also stores the second encryption key (516) which has been further encrypted by a key (520) that is unique to the device used to receive the program material. <IMAGE>
The life cycle of chondrocytes in the developing skeleton

Cartilage serves multiple functions in the developing embryo and in postnatal life. Genetic mutations affecting cartilage development are relatively common and lead to skeletal malformations, dysfunction or increased susceptibility to disease or injury. Characterization of these mutations and investigation of the molecular pathways in which these genes function have contributed to an understanding of the mechanisms regulating skeletal patterning, chondrogenesis, endochondral ossification and joint formation. Extracellular growth and differentiation factors including bone morphogenetic proteins, fibroblast growth factors, parathyroid hormone-related peptide, extracellular matrix components, and members of the hedgehog and Wnt families provide important signals for the regulation of cell proliferation, differentiation and apoptosis. Transduction of these signals within the developing mesenchymal cells and chondrocytes results in changes in gene expression mediated by transcription factors including Smads, Msx2, Sox9, signal transducer and activator of transcription (STAT), and core-binding factor alpha 1. Further investigation of the interactions of these signaling pathways will contribute to an understanding of cartilage growth and development, and will allow for the development of strategies for the early detection, prevention and treatment of diseases and disorders affecting the skeleton.
Compound 530377: 1-Propanol, 3-(3,4-dihydroxyphenyl), tris-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-trimethylsilyloxy-4-(3-trimethylsilyloxypropyl)phenoxy]silane. Molecular Formula: C18H36O3Si3. Molecular Weight: 384.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399897-T1: [Translated] DEVICE AND METHOD FOR FINISHING PIECES OF A SUBSTRATE, PARTICULARLY A TEXTILE SUBSTRATE, IN PIECES OR PARTS, UNDER HIGH PRESSURE

Device for the piece-wise or batch-wise refining of pieces of a substrate, in particular a textile substrate, under high pressure with a treatment medium, comprising: a substantially cylindrical pressure vessel ( 1 ), which is provided with a closable feed aperture ( 4 ) for placing the pieces of substrate in the pressure vessel ( 1 ); a pipe system ( 7 ) for feeding a treatment medium to and discharging it from the pressure vessel ( 1 ) under high pressure during treatment. The cylindrical pressure vessel is provided on at least one of the two end faces with an aperture that is closable by a lid ( 2, 3 ), which aperture forms the feed aperture ( 4 ). The device comprises retaining means for keeping the lid ( 2, 3 ) in place in a sealing manner during treatment, and the retaining means comprise a bounding frame ( 10 ) that is circumferentially closed, with two interconnected end pieces ( 11, 12 ) situated at a distance from each other, which end pieces in a closed position can be slid over the pressure vessel ( 1 ) and thereby retain the end faces of the pressure vessel ( 1 ) in the axial direction.
Gene therapy for lipid disorders

Lipid disorders are associated with atherosclerotic vascular disease, and therapy is associated with a substantial reduction in cardiovascular events. Current approaches to the treatment of lipid disorders are ineffective in a substantial number of patients. New therapies for refractory hypercholesterolemia, severe hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol are needed: somatic gene therapy is one viable approach. The molecular etiology and pathophysiology of most of the candidate diseases are well understood. Animal models exist for the diseases and in many cases preclinical proof-of-principle studies have already been performed. There has been progress in the development of vectors that provide long-term gene expression. New clinical gene therapy trials for lipid disorders are likely to be initiated within the next few years.
RxNorm

RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software, including those of First Databank, Micromedex, Gold Standard, and Multum. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary.

Technical documentation at http://www.nlm.nih.gov/research/umls/rxnorm/docs/index.html
Nalmefene hydrochloride

Zurnai is a prescription medication containing nalmafene hydrochloride, an opioid antagonist used to reverse opioid overdose effects. It's administered as an injection via autoinjector into the muscle or under the skin, with each dose providing 1.5 mg in 0.5 mL. Manufactured by Purdue Pharma L.P., it's approved for emergency use. This information was generated using AI and is provided for informational and research purposes only.
Treatment Episode Data Set (TEDS): 2013, National Discharge From Substance Abuse Treatment Services

This report presents data from the Treatment Episode Data Set (TEDS) for discharges from treatment in 2013. It is a companion to the reports Treatment Episode Data Set (TEDS): 2003-2013 National Admissions to Substance Abuse Treatment and Treatment Episode Data Set (TEDS): 2003-2013 State Admissions to Substance Abuse Treatment. These reports provide information on the demographic and substance abuse characteristics of substance abuse treatment admissions and discharges aged 12 and older in facilities that report to individual state administrative data systems. In addition, characteristics used to analyze changes from admission to discharge among the linked admission and discharge records are included. Primary substance of abuse, frequency of use, and employment status at admission are repeated in several tables. This is done so that characteristics at admission and discharge can be appropriately compared with each other and to ensure the inclusion of important data that might otherwise be overlooked. Data in this report include records for discharges during calendar year 2013 that were received and processed through February 1, 2016.
Elk Creek Seismic Waveforms 2011 (Part 2 of 19)

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 10 of 48 and corresponds to the time range between January 10, 2010, and January 17, 2010.
Compound 525784: 2-Methyl-4-ethyl-5-propyloxazole

Chemical compound data from PubChem database. IUPAC Name: 4-ethyl-2-methyl-5-propyl-1,3-oxazole. Molecular Formula: C9H15NO. Molecular Weight: 153.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
DPM OC, EC and FT-IR data (Quantifying elemental and organic carbon in diesel particulate matter by mid infrared spectrometry).

A method for the quantification of airborne organic carbon (OC) and elemental carbon (EC) within aerosolized diesel particulate matter (DPM) is described in the article cited below. DPM is a known carcinogen encountered in many industrial workplaces (notably mining) and in the ambient atmosphere. The method described here collects DPM particles onto a quartz fiber filter, after which reflection-mode infrared spectra are measured on a mid-infrared Fourier transform (FT-IR) spectrometer. Several infrared absorption bands are investigated for their efficacy in quantifying OC and EC. The thermo-optical (T-O) method is used to calibrate a linear regression model to predict OC and EC from the infrared spectra. The calibrated model, generated from laboratory DPM samples, is then utilized to quantify OC and EC in
mine samples obtained from two metal mine locations under a variety of operating conditions. The feasibility of further improving these results by partial least squares (PLS) regression was investigated. A single calibration that is broadly applicable would be considered an improvement over currently available portable instruments, which require aerosol-specific calibration.
Compound 528144: 5-Sec-butyl-2-chloro-3-methylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 5-butan-2-yl-2-chloro-3-methylpyrazine. Molecular Formula: C9H13ClN2. Molecular Weight: 184.66. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2023 National Directory of Mental Health Treatment Facilities

TheNational Directory of Mental Health Treatment Facilities - 2023is a listing of federal, state, and local government facilities and private facilities that provide mental health treatment services. It includes treatment facilities that responded to the 2022 National Substance Use and Mental Health Services Survey (N-SUMHSS). The information about each facility that appears in this Directory was provided by that facility in response to the 2022 N-SUMHSS. The N-SUMHSS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA). The 2023 Directory is available in PDF and Excel formats.The Directory is ordered alphabetically by state, by city within each state, and by facility name within each city. Each facility listing includes codes that represent the services offered and other features of the facility, including codes that indicate services for hearing impaired and non-English-speaking clients. Codes are defined in a key shown on pages v-x of the PDF file and as a separate tab on the Excel version. Please note services offered by a particular facility may change over time. It is suggested to verify the information in this Directory when contacting a facility.
Multiparameter Intelligent Monitoring in Intensive Care II (MIMIC-II)

<p>The objective of this Bioengineering Research Partnership is to focus the resources of a powerful interdisciplinary team from academia (MIT), industry (Philips Medical Systems) and clinical medicine (Beth Israel Deaconess Medical Center) to develop and evaluate advanced ICU patient monitoring systems that will substantially improve the efficiency, accuracy and timeliness of clinical decision making in intensive care.</p>
Compound 526358: 3,9-Dibromo-1,2,6,7-tetrachloro-dibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 3,9-dibromo-1,2,6,7-tetrachlorodibenzo-p-dioxin. Molecular Formula: C12H2Br2Cl4O2. Molecular Weight: 479.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529295: 2-Methylamino-5-chloro-2'-fluorobenzophenone

Chemical compound data from PubChem database. IUPAC Name: [5-chloro-2-(methylamino)phenyl]-(2-fluorophenyl)methanone. Molecular Formula: C14H11ClFNO. Molecular Weight: 263.69. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Identification of conserved C2H2 zinc-finger gene families in the Bilateria

Background:
          Identification of orthologous relationships between genes from widely divergent taxa allows partial reconstruction of the gene complement of ancestral genomes. C2H2 zinc-finger genes are one of the largest and most complex gene superfamilies in metazoan genomes, with hundreds of members in the human genome. Here we analyze C2H2 zinc-finger genes from three taxa - Drosophila, Caenorhabditis elegans and human - from which near-complete genome sequence data are available.
        
        
          Results:
          Our analyses conclusively identify 39 families of genes, of which 38 can be defined as orthology groups in that they are descended from single ancestral genes in the common ancestor of Drosophila, C. elegans and humans.
        
        
          Conclusions:
          On the basis of current metazoan phylogeny, these 39 groups represent the minimum complement of C2H2 zinc-finger genes present in the genome of the bilaterian common ancestor.